newsfilter
← Latest News
GlobeNewswire·

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026